AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis - PMLiVE The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

#AbbVie #Rinvoq #upadacitinib #giantcellarteritis #oralJAKinhibitor #JAKinhibitor #marketingauthorisation #Januskinaseinhibitor #SELECTGCAtrial #immunology #pharma #pharmaceuticals
zurl.co/ovP8I